Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing
Executive Summary
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
You may also be interested in...
Finance Watch: Prime Medicine Launches Second-Largest IPO In Second Half Of 2022
Public Company Edition: Prime Medicine raised $175m, making its offering the sixth-largest out of 19 biopharma IPOs in the US this year. Also, Oculis and AUM opted to go public via SPAC mergers, Insmed raised $775m from multiple financings and Dice capitalized on positive data with a $300m offering.
Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.
Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.